# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame duri...
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threa...
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a...
New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for ad...
Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new ...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...